AI filing briefs · archive

8-K filings in March 2026, explained

815 material Form 8-K filings that 659 companies we cover made with the SEC in March 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 815 briefs match

newest first · times in ET

MDTMedtronic plc Mar 24, 4:42 PM ET

Medtronic cuts FY2026 EPS guidance to $5.50-$5.54 on MiniMed charges

Negative guidance Written later 7.01

Medtronic lowered its fiscal 2026 non-GAAP EPS guidance to $5.50 to $5.54, down from $5.62 to $5.66 given on its Q3 earnings call. The cut reflects a $157 million one-time MiniMed charge tied to Blackstone payments and dilution from the March 9, 2026 MiniMed IPO, which together hit fourth-quarter results. Fiscal 2027 high single-digit EPS growth guidance was left unchanged.

FY2026 non-GAAP EPS guidance now $5.50 to $5.54, versus $5.62 to $5.66 previously
One-time $157 million MiniMed charge expected in Q4 FY2026, about $0.08 per share impact
IPO of 10% of MiniMed closed March 9, 2026, with about $0.04 per share dilution in Q4 FY2026
FDA cleared the MiniMed Flex insulin pump on March 18, 2026, several months earlier than anticipated

Read the filing on SEC.gov ↗

AIRAAR CORP Mar 24, 4:36 PM ET

AAR raises FY2026 sales growth outlook to about 19% as Q3 sales rise 25%

Positive guidance Written later 2.02

AAR reported fiscal third-quarter 2026 sales of $845.1 million, up 25% from a year earlier, and GAAP diluted earnings of $1.71 per share, compared with a loss of $0.25 per share in the prior-year quarter. The company raised its full-year fiscal 2026 total sales growth forecast to about 19% from approaching 17%, which supports the earnings outlook for shareholders, though GAAP profit included a $35.7 million bargain purchase gain.

Q3 sales were $845.1 million, up from $678.2 million; GAAP diluted EPS was $1.71 versus a loss of $0.25 a year earlier.
Adjusted diluted EPS was $1.25, up from $0.99; adjusted EBITDA was $102.1 million, up 26%.
Full-year FY2026 total sales growth guidance was raised to about 19% from approaching 17%; organic growth guidance to about 12% from approaching 11%.
Net leverage was 2.17x as of February 28, 2026, which the company says is within its 2.0x to 2.5x target range.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.